IGHV unmutated status influences outcome more than IGHV1-69 gene usage per se in patients with chronic lymphocytic leukemia

Research output: Contribution to journalArticle


In this study, IGHV1-69 gene usage was detected in 46 out of 379 cases (12%) of chronic lymphocytic leukemia (CLL). In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic hypermutation (unmutated cases, 87% vs. 35%; P = .00001), and expressed unfavorable biologic characteristics. In 12 patients (26%), common amino acid motifs within the heavy-chain third complementarity-determining region were identified, allowing assignment to previously reported stereotyped subsets. In our study, treatment-free survival of patients with unmutated IGVH1-69 did not differ significantly from that of patients expressing unmutated alternative IGHV genes. As such, IGHV1-69 gene usage per se did not seem to be predictive of progressive disease, progression being primarily related to the unmutated IGHV profile.

Original languageEnglish
Pages (from-to)390-393
Number of pages4
JournalClinical Lymphoma and Myeloma
Issue number5
Publication statusPublished - Oct 1 2009



  • Binet stage
  • CD38
  • Gene rearrangement
  • HCDR3
  • ZAP70

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this